We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App




Rapid Bacterial Infection Test Differentiates Between MRSA and MSSA in 53 Minutes

By HospiMedica International staff writers
Posted on 18 Jul 2023
Print article
Image: The Vivalytic MRSA/MSSA Rapid Test provides a quick diagnosis of methicillin resistance at the point of care (Photo courtesy of Randox)
Image: The Vivalytic MRSA/MSSA Rapid Test provides a quick diagnosis of methicillin resistance at the point of care (Photo courtesy of Randox)

Methicillin-resistant Staphylococcus aureus (MRSA) is a critical pathogen responsible for numerous hospital-acquired infections, leading to complications and increased mortality rates. The World Health Organization has estimated that patients infected with MRSA experience a mortality rate approximately 50% higher than those affected by non-resistant strains of Staphylococcus aureus. Therefore, swiftly and accurately determining whether the bacterial strain is methicillin-sensitive (MSSA) or resistant is crucial, particularly in emergency situations. Conducting MRSA/SA screening plays a significant role in mitigating health risks by curtailing contamination, breaking the chain of infection, and combating superbugs and antimicrobial resistance. Now, a rapid test provides differentiation between MRSA and MSSA in 53 minutes at the point of care.

The Vivalytic MRSA/MSSA Rapid Test from Randox Laboratories (Crumlin, UK) is a qualitative RT-PCR diagnostic test capable of identifying and distinguishing MRSA, MSSA, and methicillin-resistant coagulase-negative Staphylococci (MRCoNS). Using a single cartridge, the Vivalytic MRSA/MSSA test facilitates a speedy diagnosis of MRSA infections, allowing for the immediate application of suitable antibiotic treatment and prevention of complications. In contrast to the 1-3 days required for traditional culture sampling, the Vivalytic test provides reliable results in less than an hour right at the point of care, making it highly applicable for use in emergency departments.

The Vivalytic analyzer has been designed to be user-friendly, delivering speedy analyses and ease of handling. The patient-to-result process comprises a simple four-step procedure. The test commences when the user scans or inputs sample information and then scans the cartridge code into the integrated Vivalytic software. The sample is then added into the cartridge slot, after which the lid is closed, and the cartridge is inserted into the Vivalytic. The touchscreen display provides a countdown to the completion of the test, and results are shown on the screen. Furthermore, multiple Vivalytic devices can be wirelessly linked, enabling simultaneous control of multiple tests, all reporting to a primary Vivalytic platform.

Related Links:
Randox Laboratories 

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Surgeon Stool with Armrests & Backrest
MR4502
New
Pressure Monitoring Mattress
Entrix NX

Print article

Channels

Critical Care

view channel
Image: The technology allows doctors to detect neurological changes early and intervene more quickly (Photo courtesy of brain4care)

Novel Technology Measures Intracranial Pressure More Accurately and Non-Invasively

Monitoring intracranial pressure (ICP), alongside factors like brain tissue oxygenation, metabolism, and electrical activity, is crucial in neurocritical care. Over the past two centuries, research has... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.